Published in Ann Intern Med on May 06, 2014
Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over Time. PLoS One (2015) 1.73
Impact of National Heart, Lung, and Blood Institute-Supported Cardiovascular Epidemiology Research, 1998 to 2012. Circulation (2015) 1.42
Exceptional opportunities in medical science: a view from the National Institutes of Health. JAMA (2015) 1.25
Risk determination and prevention of breast cancer. Breast Cancer Res (2014) 1.11
Investing in clinical science: make way for (not-so-uncommon) outliers. Ann Intern Med (2014) 0.77
New insights into treatment of osteoporosis in postmenopausal women. RMD Open (2015) 0.76
An update on testosterone, HDL and cardiovascular risk in men. Clin Lipidol (2015) 0.75
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials (2015) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
The estimation of a preference-based measure of health from the SF-36. J Health Econ (2002) 14.18
Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med (1992) 12.89
Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med (1991) 8.66
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med (1999) 7.68
Utilities and quality-adjusted life years. Int J Technol Assess Health Care (1989) 4.18
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ (1999) 3.82
Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol (1998) 3.57
Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation (1987) 3.49
Handling uncertainty in cost-effectiveness models. Pharmacoeconomics (2000) 3.37
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause (2012) 2.12
Expected value of sample information calculations in medical decision modeling. Med Decis Making (2004) 2.04
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Do oncologists believe new cancer drugs offer good value? Oncologist (2006) 1.80
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. Health Econ (2004) 1.48
The value of information and optimal clinical trial design. Stat Med (2005) 1.34
The use of QALYs in clinical and patient decision-making: issues and prospects. Value Health (2009) 1.32
Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2013) 1.25
Estimating the NIH efficient frontier. PLoS One (2012) 1.20
Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ (2006) 1.18
The impact of clinical trials on the use of hormone replacement therapy. A population-based study. J Gen Intern Med (2005) 1.14
The social value of a QALY: raising the bar or barring the raise? BMC Health Serv Res (2011) 1.13
Willingness to pay for a QALY. Health Econ (2003) 1.03
Moving the QALY forward: rationale for change. Value Health (2009) 0.95
The benefits and risks of hormone replacement therapy: an epidemiologic overview. Am J Obstet Gynecol (1992) 0.88
Editorial: Moving the QALY forward or just stuck in traffic? Value Health (2009) 0.86
Expected net present value of sample information: from burden to investment. Med Decis Making (2012) 0.84
Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message. Value Health (2009) 0.83
Cost-effectiveness of hormone therapy in the United States. J Womens Health (Larchmt) (2009) 0.81
Assessing the economic impact of chronic conditions in postmenopausal women. Expert Opin Pharmacother (2005) 0.80
Current perspectives on benefits and risks of hormone replacement therapy. Am J Obstet Gynecol (2001) 0.80
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials (2003) 9.97
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 4.91
Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care (2002) 4.88
Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care (2006) 4.62
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms. Ann Intern Med (2013) 4.45
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med (2010) 4.27
One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring) (2009) 4.08
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst (2010) 4.04
Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst (2007) 3.93
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2008) 3.73
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr (2005) 3.55
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol (2013) 3.08
Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care (2006) 3.06
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Sexual orientation, health risk factors, and physical functioning in the Nurses' Health Study II. J Womens Health (Larchmt) (2004) 3.01